Literature DB >> 31069585

Temporal dynamics of peripheral neutrophil and lymphocytes following acute ischemic stroke.

Ashley B Petrone1,2,3,4, Rhae D Eisenman5, Kelsey N Steele5, Lindsey T Mosmiller5, Ogaga Urhie5, Matthew J Zdilla6,7,8.   

Abstract

BACKGROUND: The immune response to acute ischemic stroke (AIS) is implicated in diagnosis, prognosis, and intervention; however, the temporal dynamics of leukocytes following AIS are poorly understood. The purpose of this study was to characterize peripheral leukocyte dynamics following AIS among individuals with poor and favorable outcomes.
METHODS: A retrospective chart review was conducted among patients with a diagnosis of AIS who were treated at a comprehensive stroke center across a 3-year timeframe. Groups were defined according to stroke outcomes. Patients with poor outcomes were distinguished from those with favorable outcomes by discharge National Institute of Health Stroke Score, infarct size, and Modified Rankin Scale. Leukocyte counts were compared among controls and AIS outcome groups.
RESULTS: The neutrophil-lymphocyte ratio (NLR) calculated at 48-72 h post-AIS was identified as the strongest predictor of outcome. NLR was significantly higher in the poor outcome group (8.68 ± 0.93) compared with both the favorable outcome (4.5 ± 0.51, p = 0.009) and control group (4.33 ± 0.66, p < 0.001). Patients with a 48-72 h NLR ≥ 4.58 were 5.58 times more likely to have a poor outcome than AIS patients with an NLR < 4.58.
CONCLUSIONS: The results of this study improve the understanding of the immune response in AIS. Low neutrophil count relative to high lymphocyte count at 48-72 h post-AIS should be considered a predictor of a favorable stroke outcome. Conversely, high neutrophil count relative to low lymphocyte count at 48-72 h post-AIS should be considered a predictor of a poor stroke outcome.

Entities:  

Keywords:  Immune; Leukocyte; Neutrophil; Neutrophil-lymphocyte ratio; Stroke

Mesh:

Year:  2019        PMID: 31069585     DOI: 10.1007/s10072-019-03919-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  43 in total

1.  Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion.

Authors:  A Shimakura; Y Kamanaka; Y Ikeda; K Kondo; Y Suzuki; K Umemura
Journal:  Brain Res       Date:  2000-03-06       Impact factor: 3.252

2.  Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic stroke patients.

Authors:  F Perini; M Morra; M Alecci; E Galloni; M Marchi; V Toso
Journal:  Neurol Sci       Date:  2001-08       Impact factor: 3.307

3.  Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation.

Authors:  U Bank; D Reinhold; C Schneemilch; D Kunz; H J Synowitz; S Ansorge
Journal:  J Interferon Cytokine Res       Date:  1999-11       Impact factor: 2.607

4.  Suppression of T-cell functions by human granulocyte arginase.

Authors:  Markus Munder; Henriette Schneider; Claudia Luckner; Thomas Giese; Claus-Dieter Langhans; Jose M Fuentes; Pascale Kropf; Ingrid Mueller; Armin Kolb; Manuel Modolell; Anthony D Ho
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

5.  Early neutrophilia is associated with volume of ischemic tissue in acute stroke.

Authors:  Brian H Buck; David S Liebeskind; Jeffrey L Saver; Oh Young Bang; Susan W Yun; Sidney Starkman; Latisha K Ali; Doojin Kim; J Pablo Villablanca; Noriko Salamon; Tannaz Razinia; Bruce Ovbiagele
Journal:  Stroke       Date:  2007-12-27       Impact factor: 7.914

6.  Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans.

Authors:  Karl Georg Haeusler; Wolf U H Schmidt; Fabian Föhring; Christian Meisel; Thomas Helms; G Jan Jungehulsing; Christian H Nolte; Katrin Schmolke; Brigitte Wegner; Andreas Meisel; Ulrich Dirnagl; Arno Villringer; Hans-Dieter Volk
Journal:  Cerebrovasc Dis       Date:  2007-11-22       Impact factor: 2.762

7.  Temporal and spatial dynamics of cerebral immune cell accumulation in stroke.

Authors:  Mathias Gelderblom; Frank Leypoldt; Karin Steinbach; Doerthe Behrens; Chi-Un Choe; Dominic A Siler; Thiruma V Arumugam; Ellen Orthey; Christian Gerloff; Eva Tolosa; Tim Magnus
Journal:  Stroke       Date:  2009-03-05       Impact factor: 7.914

8.  Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke.

Authors:  Antje Vogelgesang; Uwe Grunwald; Sönke Langner; Robert Jack; Barbara M Bröker; Christof Kessler; Alexander Dressel
Journal:  Stroke       Date:  2007-11-29       Impact factor: 7.914

9.  Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.

Authors:  Li Zhang; Zheng Gang Zhang; Rui Lan Zhang; Mei Lu; Michael Krams; Michael Chopp
Journal:  Stroke       Date:  2003-06-12       Impact factor: 7.914

Review 10.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

View more
  12 in total

1.  Monocyte-to-Lymphocyte Ratio is Associated with Depression 3 Months After Stroke.

Authors:  Kai-Qi Ding; Ze-Hua Lai; Yu Zhang; Guo-Yuan Yang; Ji-Rong He; Li-Li Zeng
Journal:  Neuropsychiatr Dis Treat       Date:  2021-03-19       Impact factor: 2.570

2.  Neutrophil to lymphocyte ratio and adverse clinical outcomes in patients with ischemic stroke.

Authors:  Kehua Quan; Anxin Wang; Xiaoli Zhang; Xia Meng; Pan Chen; Hao Li; Yongjun Wang
Journal:  Ann Transl Med       Date:  2021-07

3.  Leukocyte Biomarkers for the Differential Diagnosis of Mild Acute Ischemic Stroke, Transient Ischemic Attack, and Stroke Mimic.

Authors:  Megan E Cavrak; Rotem Hass; Ronald J Stephens; Amelia Adcock; Ashley B Petrone
Journal:  Cureus       Date:  2021-02-16

Review 4.  The Neutrophil to Lymphocyte Ratio in Poststroke Infection: A Systematic Review and Meta-Analysis.

Authors:  Shokoufeh Khanzadeh; Brandon Lucke-Wold; Fatemeh Eshghyar; Katayoun Rezaei; Alec Clark
Journal:  Dis Markers       Date:  2022-03-12       Impact factor: 3.434

5.  Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: A systematic review and meta-analysis.

Authors:  Zhen Ye; Tingyi Hu; Jin Wang; Ruoyi Xiao; Xibei Liao; Mengsi Liu; Zhen Sun
Journal:  Front Cardiovasc Med       Date:  2022-08-08

6.  Predicting the One-Year Prognosis and Mortality of Patients with Acute Ischemic Stroke Using Red Blood Cell Distribution Width Before Intravenous Thrombolysis.

Authors:  Bo-Xi Ke; Xu Zhang; Wei-Yi Ye; Jia Li; Xiang Li; Xue-Zhi Yang; Yi-Yun Weng; Wei-Wei Xiang; Ou Zhang
Journal:  Clin Interv Aging       Date:  2020-02-20       Impact factor: 4.458

7.  Predictive Value of Routine Peripheral Blood Biomarkers in Alzheimer's Disease.

Authors:  Xiaoyu Dong; Jianfei Nao; Jile Shi; Dongming Zheng
Journal:  Front Aging Neurosci       Date:  2019-12-05       Impact factor: 5.750

8.  Association between neutrophil-to-lymphocyte ratio and major postoperative complications after carotid endarterectomy: A retrospective cohort study.

Authors:  Yun Yu; Wei-Hua Cui; Chan Cheng; Yu Lu; Qing Zhang; Ru-Quan Han
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

9.  Investigation of the peripheral inflammation (neutrophil-lymphocyte ratio) in two neurodegenerative diseases of the central nervous system.

Authors:  Sonat Pınar Kara; Bengü Altunan; Aysun Unal
Journal:  Neurol Sci       Date:  2021-07-31       Impact factor: 3.830

10.  Systemic Immune-Inflammation Index Predicts 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.

Authors:  Yiyun Weng; Tian Zeng; Honghao Huang; Junli Ren; Jianing Wang; Chenguang Yang; Wenjing Pan; Jingyu Hu; Fangyue Sun; Xinbo Zhou; Haojie Qiu; Yufan Gao; Beibei Gao; Lifen Chi; Guangyong Chen
Journal:  Clin Interv Aging       Date:  2021-05-20       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.